8,895 reports of this reaction
4.2% of all SACUBITRIL AND VALSARTAN reports
#3 most reported adverse reaction
DYSPNOEA is the #3 most commonly reported adverse reaction for SACUBITRIL AND VALSARTAN, manufactured by Novartis Pharmaceuticals Corporation. There are 8,895 FDA adverse event reports linking SACUBITRIL AND VALSARTAN to DYSPNOEA. This represents approximately 4.2% of all 209,561 adverse event reports for this drug.
SACUBITRIL AND VALSARTAN has an overall safety score of 85 out of 100. Patients taking SACUBITRIL AND VALSARTAN who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among SACUBITRIL AND VALSARTAN users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for SACUBITRIL AND VALSARTAN:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 8,895 FDA reports for SACUBITRIL AND VALSARTAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 4.2% of all adverse event reports for SACUBITRIL AND VALSARTAN, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking SACUBITRIL AND VALSARTAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.